biostudies-literatureUnknown9(5)Rodriguez-Rodriguez R<h4>Introduction</h4>The pathogenesis of renal disease in obesity and metabolic syndrome (MS) is mostly unknown. This is in part because of the limited information about renal morphological changes in these conditions. We evaluated renal histology in subjects with MS and those without MS, who are participants in the European Nephrectomy Biobank (ENBiBA) project.<h4>Methods</h4>MS was defined with at least 3 of the following criteria: (i) body mass index (BMI) ≥27 kg/m²; (ii) prediabetes: fasting glucose of 100-125 mg/dl or HbA1c >5.7%; (iii) systolic or diastolic blood pressure >140/90 mm Hg or the use of medications; and (iv) triglycerides >150 mg/dl or high-density lipoprotein cholesterol <40 (in men) or 50 mg/dl (in women). The absence of these criteria defined patients withoKidney international reports1419-1428https://www.ebi.ac.uk/biostudies/studies/S-EPMC11068944biostudies-literatureRenal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia.PMC11068944Diaz MNGiacomo DIbernon MVieira MBAutran-Gomez Pablo Cannata AMRodriguez Rodriguez AEGhanem FPraga MPorrini EMena NNHojs ROrtiz AMorales ERodriguez-Rodriguez RPujol LFeldt-Rasmussen Alberto Ortiz BQuero MMontserrat Goma SBTrevisani FBagi PCases Corona CMBettiga ALopez-Martinez Mads Hornum MSalonia AMontorsi FHornum MCarro CGStock da Cunha TMiguel Bigotte Vieira LMDi Marco FBevc SCruzado JMDIABESITY working group of the European Renal AssociationFernandez GGonzalez-Enguita CFrancesco TKhazim KMoreso FGarranzo MFernandez-Fernandez BSanz ABLaranjinhia IMendonca LSorensen CAGoma-Garces EFeldt-Rasmussen BIvo Laranjinhia TCCruzado JfalseRenal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia.<h4>Introduction</h4>The pathogenesis of renal disease in obesity and metabolic syndrome (MS) is mostly unknown. This is in part because of the limited information about renal morphological changes in these conditions. We evaluated renal histology in subjects with MS and those without MS, who are participants in the European Nephrectomy Biobank (ENBiBA) project.<h4>Methods</h4>MS was defined with at least 3 of the following criteria: (i) body mass index (BMI) ≥27 kg/m²; (ii) prediabetes: fasting glucose of 100-125 mg/dl or HbA1c >5.7%; (iii) systolic or diastolic blood pressure >140/90 mm Hg or the use of medications; and (iv) triglycerides >150 mg/dl or high-density lipoprotein cholesterol <40 (in men) or 50 mg/dl (in women). The absence of these criteria defined patients witho2024-01-01T00:00:00Z2024 May2026-04-12T15:29:21.592Z2026-04-07T13:17:50.765ZS-EPMC110689443870782310.1016/j.ekir.2024.02.1403